<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089881</url>
  </required_header>
  <id_info>
    <org_study_id>200706006M</org_study_id>
    <nct_id>NCT01089881</nct_id>
  </id_info>
  <brief_title>The Effectiveness of 18F-fluorocholine Positron Emission Tomography (PET) in Detecting, Staging and Following-up Prostate Cancer</brief_title>
  <official_title>The Effectiveness of 18F-fluorocholine PET in Detecting, Staging and Following-up Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Choline is one of the components of phosphatidylcholine, an essential element of&#xD;
      phospholipids in the cell membrane. Some malignant cells show their ability to actively&#xD;
      incorporate choline to produce phosphocholine and phosphatidylcholine to facilitate tumor&#xD;
      cell duplication. The efficacy of 18F-fluorocholine (18F-FCH) for localizing primary or&#xD;
      metastatic prostate cancer has been recently reported in limited studies. This study will be&#xD;
      conducted to delineate the effectiveness of 18F-FCH PET in (1) differentiating benign&#xD;
      prostate hypertrophy (BPH) from prostate cancer, (2) staging prostate cancer, (3)&#xD;
      following-up patients with prostate cancer after initial curative therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Prostate cancer is a leading cause of cancer death for male in Taiwan. Although 18F-FDG PET&#xD;
      has been shown to be an effective tool in diagnosing many malignancies, previous studies have&#xD;
      shown that 18F-FDG is not a suitable PET tracer for detecting prostate cancer. Choline is one&#xD;
      of the components of phosphatidylcholine, an essential element of phospholipids in the cell&#xD;
      membrane. Some malignant cells show their ability to actively incorporate choline to produce&#xD;
      phosphocholine and phosphatidylcholine to facilitate tumor cell duplication. The efficacy of&#xD;
      18F-fluorocholine (18F-FCH) for localizing primary or metastatic prostate cancer has been&#xD;
      recently reported in limited studies.&#xD;
&#xD;
      Purpose:&#xD;
&#xD;
      This study will be conducted to delineate the effectiveness of 18F-FCH PET in (1)&#xD;
      differentiating benign prostate hypertrophy (BPH) from prostate cancer, (2) staging prostate&#xD;
      cancer, (3) following-up patients with prostate cancer after initial curative therapy.&#xD;
&#xD;
      Patients and Methods:&#xD;
&#xD;
      This study will include&#xD;
&#xD;
        1. Group 1: 50 patients with BPH&#xD;
&#xD;
        2. Group 2: 50 patients with newly diagnosed prostate cancer and&#xD;
&#xD;
        3. Group 3: 50 patients who have received curative treatment for prostate cancer and are&#xD;
           suspicious of recurrence/metastases because of a persistent increase in their serum PSA.&#xD;
&#xD;
      18F-FCH whole-body PET will be performed for each patient&#xD;
&#xD;
      Expected Results:&#xD;
&#xD;
      To evaluate the effectiveness of 18F-FCH in the diagnosis, staging and follow-up of prostate&#xD;
      cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>patients with BPH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>patients with newly diagnosed prostate cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <description>patients who have received curative treatment for prostate cancer and are suspicious of recurrence/metastases because of a persistent increase in their serum PSA.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        1. Group 1: 50 patients with BPH&#xD;
&#xD;
          2. Group 2: 50 patients with newly diagnosed prostate cancer and&#xD;
&#xD;
          3. Group 3: 50 patients who have received curative treatment for prostate cancer and are&#xD;
             suspicious of recurrence/metastases because of a persistent increase in their serum&#xD;
             PSA.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Group 1: 50 patients with BPH&#xD;
&#xD;
          1. Age above 35 years old&#xD;
&#xD;
          2. Histologically confirmed BPH&#xD;
&#xD;
          3. Informed consent signed&#xD;
&#xD;
        Group 2: 50 patients with newly diagnosed prostate cancer and&#xD;
&#xD;
          1. Age above 35 years old&#xD;
&#xD;
          2. Histologically confirmed prostate cancer&#xD;
&#xD;
          3. Informed consent signed&#xD;
&#xD;
        Group 3: 50 patients who have&#xD;
&#xD;
          1. Age above 35 years old&#xD;
&#xD;
          2. Histologically confirmed prostate cancer and had received curative treatment for&#xD;
             prostate cancer&#xD;
&#xD;
          3. suspicious of recurrence/metastases because of a persistent increase in their serum&#xD;
             PSA&#xD;
&#xD;
          4. Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with other known malignancies will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Hong Jeng, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu-Hong Jeng, M.D.</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>62134</phone_ext>
    <email>Yhj5251@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei,</city>
        <zip>10043</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Hong Jeng, M.D.</last_name>
      <phone>886-2-23123456</phone>
      <phone_ext>62134</phone_ext>
      <email>Yhj5251@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2010</study_first_posted>
  <last_update_submitted>March 18, 2010</last_update_submitted>
  <last_update_submitted_qc>March 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hong-Jeng Yu</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>18F-fluorocholine</keyword>
  <keyword>PET</keyword>
  <keyword>recurrence</keyword>
  <keyword>metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

